A low-dose finasteride foam with more than one job.
A compounded foam pairing low-dose topical finasteride with GHK-Cu and latanoprost in a no-drip format.
About 10 minutes. No charge unless your clinician approves.
Three actives. One serious topical plan.
Hair loss treatment gets complicated quickly when one active is no longer the entire strategy. Separate bottles, separate application steps, separate reasons each ingredient is there. This compounded foam consolidates finasteride, GHK-Cu, and latanoprost into one topical prescription.
The convenience matters, but the combination is the real story.
Finasteride addresses the hormonal pathway involved in follicle miniaturization. GHK-Cu is included for its role in connective-tissue, collagen, and remodeling signaling. Latanoprost is a prescription molecule borrowed from another area of medicine and used here in a compounded scalp preparation. Your clinician decides whether this specific combination makes sense for your case and places it into one manageable routine.
Topical also does not mean trivial. Finasteride can be absorbed through the scalp, which is why medical history, side-effect discussion, and ongoing review still belong around the prescription.
You receive a clear explanation of each ingredient's role, the low-dose topical finasteride, the foam format, and the questions your clinician will monitor after prescribing.
Read the evidence →For the hair plan that has moved beyond one ingredient.
Single-Active Treatment Is No Longer the Whole Conversation
You have already moved past the idea that one ingredient automatically answers every part of your hair-loss plan. You want a clinician to decide whether a more layered topical approach is justified.
You Prefer to Keep Finasteride Topical
You would rather use finasteride on the scalp than add a daily oral tablet, while keeping the rest of the topical plan in the same application.
You Want Complexity Managed for You
Three prescription actives are not a DIY stacking invitation. You want one formula, one set of instructions, and a clinician responsible for whether the combination belongs together.
Compounded by a licensed pharmacy and not an FDA-approved drug product. Topical finasteride is still absorbed systemically, so a licensed provider reviews your full history, including pregnancy status, before prescribing. Results vary.
This might not be the right fit if:
- Women who are or may become pregnant should not use or handle the finasteride-containing foam
- Known hypersensitivity to finasteride, copper, or latanoprost
- Active scalp irritation, infection, or broken skin at the application site
- Pregnancy or breastfeeding
- Known copper sensitivity or Wilson’s disease
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Finasteride / GHK-Cu / Latanoprost Foam, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- One compounded foam combining finasteride, GHK-Cu, and latanoprost
- Prepared to your individual prescription by a licensed 503A pharmacy
- Applied to the scalp as directed by your provider
- Continued use is required to maintain treatment benefit
- Response and tolerance reviewed through your ongoing provider relationship
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
More in Beauty & Skin.
Glutathione
Antioxidant defense, under clinical direction.
Compounded injectable glutathione for clinician-guided antioxidant defense beyond the supplement aisle.
GHK-Cu Copper Peptide Cream
Prescription strength. Every percentage disclosed.
Prescription-compounded GHK-Cu cream in disclosed 2% and 4% strengths, not a mystery cosmetic complex.
Minoxidil
One daily tablet. Hair treatment out of sight.
One daily oral minoxidil tablet for people who want prescription hair care without a topical routine.
What the research shows
Topical finasteride spray beat placebo on hair count, close to oral finasteride.
The detail
For the finasteride component by the topical route: in a 24-week randomized, double-blind, double-dummy, parallel-group phase III trial in adult male outpatients with androgenetic alopecia at 45 European sites, 458 randomized and 323 completing, a topical finasteride 0.25 percent spray increased target area hair count by an adjusted mean of 20.2 hairs versus 6.7 hairs on placebo, and the result was numerically similar to oral finasteride 1 mg.1
In a 16-man pilot, latanoprost raised hair density on the treated scalp zone.
The detail
For the latanoprost component: in a 24-week randomized, double-blind, placebo-controlled pilot study in 16 men with mild androgenetic alopecia, latanoprost 0.1 percent applied daily to a marked scalp zone increased hair density compared with both baseline and the placebo-treated zone on the same scalp.2
Hair count rose on all three latanoprost strengths, with only two women on vehicle.
The detail
In a randomized, double-blind, single-center dose-ranging pilot trial in 29 adult women with female androgenetic alopecia treated once daily for six months, topical latanoprost acid increased target area hair count within participants across all three active arms, by 17.8, 23.5 and 16.5 hairs per square centimeter at 0.01, 0.05 and 0.1 percent respectively, with no significant differences between arms and only two women assigned to vehicle.3
GHK-Cu stimulated collagen synthesis in cultured cells, not in a person.
The detail
For the copper-peptide component: in cultured human fibroblasts, GHK-Cu stimulated collagen synthesis beginning between 10 to the minus 12 and 10 to the minus 11 molar and peaking at 10 to the minus 9 molar, independent of any change in cell number. This is laboratory cell culture, not treatment of a person.4
A GHK peptide complex raised hair count over placebo, but not length or thickness.
The detail
In a 6-month randomized, placebo-controlled trial in 45 patients with male pattern hair loss, a complex of 5-aminolevulinic acid with glycyl-histidyl-lysine peptide applied once daily increased hair count by 52.6 in the higher-strength group and 71.5 in the lower-strength group versus 9.6 on placebo, with a statistically significant difference in the ratio of change between the lower-strength group and placebo, and no significant differences in hair length or thickness.5
What it does not show
No trial has tested this foam.
The detail
No trial has tested this foam. There is no randomized controlled trial of finasteride, GHK-Cu and latanoprost combined in one topical preparation, and no comparison of the combination against any single component or against vehicle. The foam is compounded to an individual prescription and is not an FDA-approved drug product; the studies above tested separate molecules, at other strengths, in other populations.12345
The finasteride evidence is in men; in women, oral finasteride matched placebo.
The detail
This formula is offered to women and the finasteride evidence is in men. The topical finasteride trial enrolled adult male outpatients only, and when oral finasteride 1 mg was tested in 137 postmenopausal women with androgenetic alopecia in a 1-year randomized, placebo-controlled trial, it did not differ from placebo on hair count or on any patient, investigator, photographic or scalp biopsy assessment.16
No trial has tested either active at the strength in this formulation.
The detail
The concentrations here sit well below the concentrations that were studied. The topical finasteride trial used a 0.25 percent spray, ten times the 0.025 percent in this foam. The scalp latanoprost work used 0.1 percent, with 0.01 percent as the lowest arm ever tested, ten to one hundred times the 0.001 percent here. No trial has tested either active at the strength in this formulation.123
GHK-Cu has no randomized trial for scalp hair.
- Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male… J Eur Acad Dermatol Venereol. 2022.
- Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the… J Am Acad Dermatol. 2012.
- Rakowska A, et al. Topical latanoprost acid for female androgenetic alopecia: a pilot… Pharmacol Rep. 2026.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the… FEBS Lett. 1988.
- Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a complex of 5-aminolevulinic acid and… Ann Dermatol. 2016.
- Price VH, et al. Lack of efficacy of finasteride in postmenopausal women with… J Am Acad Dermatol. 2000.
Do not use if you have
- Pregnancy, where finasteride is contraindicated because it can affect the development of a male fetus
- Anyone who is or may become pregnant should not use or handle this foam
Serious risks
- Finasteride does not stay entirely on the scalp, so approved oral finasteride labeling still matters
- Oral finasteride labeling records decreased libido, sexual dysfunction, breast tenderness and enlargement
- Postmarketing reports of depression and suicidal ideation
- Latanoprost is used here outside its approved purpose of lowering eye pressure
- Its ophthalmic labeling documents increased brown pigmentation of the iris that is likely to be permanent, darkening of eyelid skin, and changes in the length, thickness, number and direction of lashes
Commonly reported
- Local irritation, redness, itching and dryness from the scalp foam
- Occasionally contact dermatitis
Because it is a foam
- That ophthalmic labeling is why the foam is kept away from the eyes, and why pigment changes or hair growth on skin the foam touches are worth reporting
GHK-Cu delivers copper, so Wilson disease and other disorders of copper handling matter, as does copper you already take from other products, and human safety data for compounded topical copper peptides are limited. The foam is compounded to your individual prescription by a licensed 503A pharmacy and is not an FDA-approved drug product, and a licensed provider decides whether this combination fits you and reviews how your scalp tolerates it.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
It can. Finasteride is absorbed through the scalp, so effects on libido or erections remain possible even in a foam. Your provider discusses that possibility openly and weighs the topical route against your history before prescribing.
Because it is compounded to your prescription, the pharmacy prepares the formula after approval rather than pulling a stock product from a shelf. Pricing is shown before you commit, and you can pause or cancel through your account if your plan changes.
Hair treatment is a months-long conversation, not a days-long one. Response varies, and continued use matters. Your clinician reviews what is actually happening over time rather than promising a fixed result by a fixed date.